Generic Name: Ketoconazole
VA Class: AM700
CAS Number: 65277-42-1
[Posted 07/26/2013] ISSUE: FDA is taking several actions related to Nizoral (ketoconazole) oral tablets, including limiting the drug’s use, warning that it can cause severe liver injuries and adrenal gland problems, and advising that it can lead to harmful drug interactions with other medications. FDA has approved label changes and added a new Medication Guide to address these safety issues. As a result, Nizoral oral tablets should not be a first-line treatment for any fungal infection. Nizoral should be used for the treatment of certain fungal infections, known as endemic mycoses, only when alternative antifungal therapies are not available or tolerated.
Liver Injury (Hepatotoxicity): Nizoral tablets can cause liver injury, which may potentially result in liver transplantation or death. FDA has revised the Boxed Warning, added a strong recommendation against its use (contraindication) in patients with liver disease, and included new recommendations for assessing and monitoring patients for liver toxicity.
Adrenal Insufficiency: Nizoral tablets may cause adrenal insufficiency by decreasing the body’s production of corticosteroids.
Drug Interactions: Nizoral tablets may interact with other drugs a patient is taking and can result in serious and potentially life-threatening outcomes, such as heart rhythm problems.
See the FDA Drug Safety Communication for additional information, including a Data Summary.
BACKGROUND: Nizoral (ketoconazole) is indicated for the treatment of fungal infections when alternatives are not available or not tolerated. The topical formulations of Nizoral have not been associated with liver damage, adrenal problems, or drug interactions. These formulations include creams, shampoos, foams, and gels applied to the skin, unlike the Nizoral tablets, which are taken by mouth.
RECOMMENDATION: Nizoral tablets should be used only for the treatment of certain life-threatening mycoses when the potential benefits outweigh the risks and alternative therapeutic options are not available or tolerated. Healthcare professionals should assess the liver status of the patient before starting oral ketoconazole, and monitor serum ALT levels during treatment. Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients under prolonged periods of stress (major surgery, intensive care, etc.). Review all concomitant medications for the potential for drug interactions with Nizoral tablets.
For more information visit the FDA website at: and .
Concomitant use with cisapride or with astemizole or terfenadine (drugs no longer commercially available in the US) is contraindicated.263 Pharmacokinetic interactions can occur and serious cardiovascular events have been reported with concomitant use.263 VT, VF, and torsades de pointes have been reported in patients receiving concomitant cisapride; death, VT, and torsades de pointes have been reported in patients receiving concomitant terfenadine.263 (See Interactions.)
Uses for Nizoral
Drugs of choice are IV amphotericin B (especially for severe infections and those involving the CNS) or oral itraconazole;234 238 264 288 290 292 296 297 298 299 332 333 fluconazole and ketoconazole are considered alternatives.238 264 288 290 292 296 297 299
Oral ketoconazole usually has been effective when used in immunocompetent individuals with mild to moderate pulmonary or extrapulmonary blastomycosis.213 220 290 291 292 297 Consider that treatment failures have been reported when ketoconazole was used for treatment of cutaneous or pulmonary blastomycosis in individuals who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.211 295 296 (See Meningitis and Other CNS Infections under Cautions.)
Has been used for treatment of uncomplicated vulvovaginal candidiasis†.340 343 344 Not a drug of choice for initial treatment; single-dose fluconazole is the only oral regimen included in current CDC recommendations for treatment of uncomplicated vulvovaginal candidiasis.270 272 Recommended by CDC and others as one of several alternatives for maintenance treatment of recurrent vulvovaginal candidiasis† in women with a history of recurrent infections.270 271 340 343 344 346
Optimum regimens for chromomycosis have not been identified.288 335 Flucytosine may be a drug of choice used alone or in conjunction with another antifungal (e.g., IV amphotericin B, oral itraconazole, oral ketoconazole).288 335
Drugs of choice are IV amphotericin B (especially for severe infections and those in immunocompromised patients including HIV-infected individuals) or oral fluconazole; itraconazole and ketoconazole are considered alternatives.234 238 279 280 288 290 292 293
Treatment of certain dermatophytoses of the skin, scalp, and nails, including tinea capitis (scalp ringworm), tinea corporis (ringworm of the body), tinea cruris (jock itch; groin ringworm), tinea pedis (athlete’s foot, foot ringworm), tinea manuum (hand ringworm), and tinea unguium (onychomycosis; nail ringworm) caused by Epidermophyton, Microsporum, or Trichophyton.263 291 324 325
Used for severe recalcitrant cutaneous dermatophyte infections in patients who have not responded to topical therapy or have not responded to or are unable to take other oral antifungals (e.g., griseofulvin).263
Tinea corporis and tinea cruris generally can be effectively treated using a topical antifungal; an oral antifungal may be necessary if the disease is extensive, dermatophyte folliculitis is present, the infection does not respond to topical therapy, or the patient is immunocompromised or has a coexisting disease.352 353 356 357 358 360 Tinea capitis and tinea barbae generally are treated using an oral antifungal.325 353 359
While topical antifungals usually are effective for treatment of uncomplicated tinea manuum and tinea pedis,353 356 358 360 an oral antifungal usually is necessary for treatment of severe, chronic, or recalcitrant tinea pedis, for treatment of chronic moccasin-type (dry-type) tinea pedis, and for treatment of tinea unguium (onychomycosis).353 357 358 360
Drugs of choice are IV amphotericin B (especially for life-threatening infections including those in HIV-infected individuals) or oral itraconazole; ketoconazole and fluconazole are considered alternatives.238 279 280 290 291 292 375
Drug of choice for initial treatment of severe infections is IV amphotericin B;238 288 291 293 310 311 335 oral azole antifungals (e.g., ketoconazole, itraconazole) can be used in patients with less severe infections.238 288 291 335
Pityriasis (Tinea) Versicolor
Pityriasis (tinea) versicolor generally can be treated topically with an imidazole-derivative azole antifungal (e.g., clotrimazole, econazole, ketoconazole, miconazole, oxiconazole, sulconazole), an allylamine antifungal (e.g., terbinafine), ciclopirox olamine, or certain other topical therapies (e.g., selenium sulfide 2.5%).234 324 352 354 355 357 An oral antifungal (e.g., itraconazole, ketoconazole) may be indicated, with or without a topical agent, in patients who have extensive or severe infections or who fail to respond to or have frequent relapses with topical therapy.324 354 355 357
Has been used in conjunction with a topical anti-infective (e.g., miconazole, neomycin, metronidazole, propamidine isethionate) in the treatment of >Acanthamoeba keratitis†.134 135 136 137 138 139 140 226 Optimum therapy for Acanthamoeba keratitis remains to be clearly established, but prolonged local and systemic therapy with multiple anti-infectives and often surgical treatment (e.g., penetrating keratoplasty) usually required.134 135 136 137 138 139 140
A regimen of oral ketoconazole, rifampin, and co-trimoxazole has been used for treatment of chronic Acanthamoeba meningitis† in several immunocompetent children.187 225 (See Meningitis and Other CNS Infections under Cautions.)
Has been used for treatment of cutaneous or mucocutaneous leishmaniasis† caused by various Leishmania spp. (e.g., Leishmania major†, L. mexicana†, L. panamensis†, L. braziliensis†, L. tropica†).203 204 205 206 207 208 209 234 250 314 316 317 Usual drugs of choice are pentavalent antimony compounds (e.g., sodium stibogluconate or meglumine antimonate [drugs not commercially available in the US]).225 234 317 319 Preferred alternatives or additional drugs of choice are IV amphotericin B (conventional or liposomal formulations) and parenteral pentamidine; other alternatives include oral azole antifungals (e.g., itraconazole, ketoconazole) or topical paromomycin (for cutaneous leishmaniasis when there is a low potential for mucosal spread).225 234 319
Has been used in a limited number of patients for treatment of antimony-resistant visceral leishmaniasis (kala-azar) caused by L. donovani†,261 262 315 317 318 but may be less effective in these infections than in the treatment of cutaneous leishmaniasis.261 262 317 Usual drugs of choice for initial treatment of visceral leishmaniasis are pentavalent antimony compounds, but resistance and treatment failures are becoming increasingly common;288 317 IV amphotericin B and pentamidine are considered alternatives.288 317 319
Because of ketoconazole’s ability to inhibit testicular and adrenal steroid synthesis, the drug has been used in the treatment of advanced prostatic carcinoma†.106 107 108 151 179 180 181 182 183 184 284 285 286 368 369
Has been used effectively for palliative treatment of Cushing’s syndrome† (hypercortisolism), including adrenocortical hyperfunction associated with adrenal or pituitary adenoma or ectopic corticotropin-secreting tumors.112 113 114 151 154 224 342
Has been used in a limited number of geriatric patients ≥75 years of age for treatment of corticotropin-dependent Cushing’s syndrome; may provide an effective alternative in patients who cannot tolerate surgical treatment.342
Hirsutism and Precocious Puberty
Has been used with some success for treatment of hypercalcemia in adults with sarcoidosis†.363 364 365 366 Has reduced serum calcium concentrations in some, but not all, patients with sarcoidosis-associated hypercalcemia;364 365 366 hypercalcemia and increased serum 1,25-dihydroxyvitamin D concentrations may recur when ketoconazole dosage is decreased or the drug discontinued.365 366
Nizoral Dosage and Administration
To ensure absorption in patients with achlorhydria, each 200-mg ketoconazole tablet should be dissolved in 4 mL of 0.2N hydrochloric acid solution263 or taken with 200 mL of 0.1N hydrochloric acid.a The resultant solution should be administered via a plastic or glass straw to avoid contact with the teeth, and a glass of water should be administered immediately after the solution.263 Alternatively, some clinicians recommend that each 200 mg of ketoconazole be given with ≥680 mg of glutamic acid hydrochloride.198 199 Other clinicians suggest that each 200 mg of ketoconazole be administered with an acidic beverage (e.g., Coca-Cola, Pepsi)273 or the dose dissolved in 60 mL of citrus juice to ensure absorption; however, this strategy may not be adequate in all patients with achlorhydria and patients should be monitored closely for therapeutic failure.273
General Pediatric Dosage
Treatment of Fungal InfectionsOral
General Adult Dosage
Treatment of Fungal InfectionsOral
Oropharyngeal and Esophageal CandidiasisOral
When used as a maintenance regimen to reduce the frequency of recurrent episodes of vulvovaginal candidiasis† in women who have received an initial intensive antifungal regimen (i.e., 7–14 days of an intravaginal azole antifungal or a 2-dose fluconazole regimen), ketoconazole has been given in a dosage of 100 mg once daily for up to 6 months.270 340 341 343 344 346
200–400 mg daily.335 Treatment usually continued for 6–12 months.
200–400 mg daily has been given for 1–2 months.a Infections involving glabrous skin require a minimum of 4 weeks of treatment; palmar and plantar infections may respond more slowly.263 Tinea unguium (onychomycosis) may require ≥6–12 months of treatment.a
A minimum of 6 months of therapy usually required, but 2–6 months has been effective in some patients.a
200–400 mg daily.335
A minimum of 6 months of therapy usually required, but 2–6 months has been effective in some patients.a
Cutaneous and Mucocutaneous Leishmaniasis†Oral
Visceral Leishmaniasis (Kala-Azar)†Oral
400 mg every 8 hours has been used for treatment of prostatic carcinoma†106 108 180 181 182 183 285 or as an adjunct in the management of disseminated intravascular coagulation (DIC) associated with prostatic carcinoma†.152 178 Risk of depressed adrenocortical function at this high dosage should be considered.263 (See Endocrine and Metabolic Effects under Cautions.)
Cautions for Nizoral
Hypersensitivity to ketoconazole.263
Concomitant use with certain drugs metabolized by CYP3A4 isoenzymes (e.g., astemizole [no longer commercially available in the US], cisapride, midazolam, terfenadine [no longer commercially available in the US], triazolam).263 (See Specific Drugs under Interactions.)
Symptomatic hepatotoxicity usually is apparent within the first few months of ketoconazole therapy (median 28 days),50 61 164 167 168 169 170 188 189 190 191 192 263 but occasionally may be apparent within 3–7 days of initiation of therapy.164 166 167 191 192 263 Although ketoconazole-induced hepatotoxicity usually is reversible following discontinuance of the drug,50 164 165 166 167 188 189 190 191 192 263 recovery may take several months;164 165 167 188 190 263 rarely, death has occurred.164 165 167 168 169 170 191 192 193 263
Most cases of hepatotoxicity have been reported in patients receiving the drug for tinea unguium (onychomycosis);50 167 168 169 188 189 190 191 192 193 263 many others were receiving the drug for chronic, refractory dermatophytoses.167 191 192 Several cases of ketoconazole-induced hepatitis have been reported in children.165 167 189 191 192 263
Monitor closely for clinical and biochemical signs of hepatotoxicity.164 166 167 169 170 192 263 Perform liver function tests (e.g., serum AST, ALT, alkaline phosphatase, γ-glutamyltransferase [γ-glutamyltranspeptidase, GGT, GGTP], bilirubin) prior to and frequently (e.g., biweekly during the first 2 months of therapy and monthly or bimonthly thereafter) during therapy, particularly in those receiving prolonged therapy, those receiving other potentially hepatotoxic drugs, and those with a history of hepatic disease.164 166 167 169 170 188 189 190 193 263
Minor, asymptomatic elevations in liver function test results may return to pretreatment concentrations during continued ketoconazole therapy.164 167 191 192 193 If liver function test results are substantially elevated or if such abnormalities persist, worsen, or are accompanied by other manifestations of hepatic dysfunction, ketoconazole should be discontinued.164 167 168 169 170 189 190 191 192
Endocrine and Metabolic Effects
Ketoconazole can inhibit testosterone synthesis and transient decreases in serum testosterone may occur;109 110 151 174 263 concentrations usually return to baseline values after the drug is discontinued.263 Testosterone concentrations are impaired with ketoconazole dosage of 800 mg daily and abolished with dosage of 1.6 g daily.263
Ketoconazole may inhibit cortisol synthesis, particularly in patients receiving relatively high daily dosage or divided daily dosing.109 112 113 114 151 154 156 157 158 159 166 173 192 229 230 The adrenocortical response to corticotropin (ACTH) may be at least transiently diminished and a reduction in urinary free and serum cortisol concentrations may occur.109 110 112 113 114 151 154 156 157 158 159 166 173 192 Adrenocortical insufficiency has been reported only rarely.109 159 160 166 173 192 229 Adrenocortical hypofunction generally is reversible following discontinuance of the drug,154 156 157 166 but rarely may be persistent.159
To minimize the risk of possible endocrine and metabolic effects, dosages greater than those usually recommended should not be used.263
Meningitis and Other CNS Infections
Because CSF concentrations of ketoconazole are unpredictable following oral administration, the drug should not be used alone to treat CNS fungal infections, including candidal, coccidioidal, or cryptococcal meningitis.263 291 302 330
Use in pediatric patients only when potential benefits justify possible risks.263 Has not been systematically studied in children of any age,263 but has been used in a limited number of children >2 years of age.263 There is essentially no information available to date on use in children <2 years of age.263
Common Adverse Effects
GI effects (nausea, vomiting), hepatic effects, pruritus.263
Interactions for Nizoral
Drugs Metabolized by Hepatic Microsomal Enzymes
Pharmacokinetic interactions likely with drugs that are substrates of CYP3A4.263
Monitor closely if used concomitantly with other potentially hepatotoxic drugs, especially in patients requiring prolonged therapy or with a history of liver disease.263 (See Hepatic Effects under Cautions.)
Disulfiram reactions (flushing, rash, peripheral edema, nausea, headache) have occurred rarely in patients who ingested alcohol while receiving ketoconazole;263 267 268 usually resolved within a few hours263
Some clinicians recommend that alcohol be avoided during and for 48 hours after discontinuance of ketoconazole therapy267
Because gastric acidity is necessary for dissolution and absorption of ketoconazole, concomitant administration of antacids may decrease absorption of the antifungal263
Administer antacids at least 2 hours after ketoconazole263
Anticoagulants, oral (warfarin)
Possible enhanced anticoagulant effects263
Monitor PT or other appropriate tests closely; adjust anticoagulant dosage if necessary263
Possible pharmacokinetic interaction with changes in metabolism of one or both drugs263
Monitor serum concentrations if used concomitantly263
Antidiabetic agents, sulfonylureas
Consider the possibility that hypoglycemia may occur when ketoconazole used concomitantly with antidiabetic agents263
Antihistamines (astemizole, loratadine, terfenadine)
Aztemizole and terfenadine (drugs no longer commercially available in the US): Pharmacokinetic interaction and potential for serious or life-threatening reactions (e.g., cardiac arrhythmias, prolonged QT interval)252 253 254 255 256 257 259 260 263 287
Loratadine: Increased plasma concentrations and AUCs of loratadine and its active metabolite, but no evidence of changes in QT interval or incidence of adverse effects263
Antimycobacterials (rifampin, isoniazid)
Do not use concomitantly with rifampin or isoniazid263
Benzodiazepines (midazolam, triazolam)
Increased plasma concentrations of midazolam or triazolam; possible prolonged sedative and hypnotic effects of the drugs263
Ketoconazole should not be used concomitantly with midazolam or triazolam263
Special precaution is required if parenteral midazolam is used in patients receiving ketoconazole because the sedative effects of midazolam may be prolonged263
Concomitant use contraindicated263
Increased plasma concentrations of digoxin reported; causative relationship unclear263
Closely monitor digoxin concentrations in patients receiving ketoconazole263
Histamine H2-receptor antagonists (e.g., cimetidine, ranitidine)
Because gastric acidity is necessary for dissolution and absorption of ketoconazole, concomitant administration of histamine H2-receptor antagonists may decrease absorption of the antifungal 263
Administer H2-receptor antagonist at least 2 hours after ketoconazole263
Immunosuppressive agents (cyclosporine, methylprednisolone, prednisone, tacrolimus)
Cyclosporine or tacrolimus: Use with caution and monitor concentrations of the immunosuppressive agent if possible; adjust cyclosporine or tacrolimus dosage if needed when ketoconazole is initiated or discontinued146 263
In vitro evidence that ketoconazole can inhibit metabolism of paclitaxel269
Clinical importance unclear; use concomitantly with caution269
Possible decreased absorption of ketoconazole362
Administer sucralfate at least 2 hours after ketoconazole362
Pending further accumulation of data, monitor serum theophylline concentrations and adjust theophylline dosage if necessary when ketoconazole is initiated or discontinued in patients receiving theophylline147
Ketoconazole must be dissolved in gastric secretions and converted to the hydrochloride salt prior to absorption from the stomach.a Bioavailability depends on the pH of the gastric contents in the stomach; an increase in pH results in decreased absorption of the drug.a (See Absorption: Special Populations.)
Effect of food on rate and extent of GI absorption of ketoconazole has not been clearly determined.162
Considerable interindividual variations in peak plasma concentrations and AUCs have been reported.a
Oral bioavailability may be decreased in patients with achlorhydria,a including those with HIV-associated gastric hypochlorhydria.198 200 Concomitant administration of dilute hydrochloric acid solution usually normalizes absorption of the drug in these patients.198 Concomitant administration of an acidic beverage may increase bioavailability in some individuals.273 (See Oral Administration under Dosage and Administration.)
Distributed into urine, bile, saliva, sebum, cerumen, and synovial fluid.a
May be distributed into CSF following oral administration, but CNS penetration is unpredictable and has generally been considered to be minimal.a
Plasma Protein Binding
Partially metabolized in the liver to several inactive metabolites by oxidation and degradation of the imidazole and piperazine rings, by oxidative O-dealkylation, and by aromatic hydroxylation.a
Major route of elimination of ketoconazole and its metabolites appears to be excretion into the feces via the bile.a
In fasting adults with normal renal function, approximately 57% of a single 200-mg oral dose is excreted in feces within 4 days (20–65% of this is unchanged drug); approximately 13% of the dose is excreted in urine within 4 days (2–4% of this is unchanged drug).a
Plasma concentrations appear to decline in a biphasic manner with a half-life of approximately 2 hours in the initial phase and 8 hours in the terminal phase.263
Plasma concentrations and half-life not substantially affected by renal or hepatic impairment.a
Well-closed container at 15–25°C; protect from moisture.263
Actions and Spectrum
Presumably exerts its antifungal activity by altering cellular membranes resulting in increased membrane permeability, leakage of essential elements (e.g., amino acids, potassium), and impaired uptake of precursor molecules (e.g., purine and pyrimidine precursors to DNA).127 128 130 131 Inhibits cytochrome P-450 14-α-desmethylase in susceptible fungi, which leads to accumulation of C-14 methylated sterols (e.g., lanosterol) and decreased concentrations of ergosterol.128 129 130 151
Spectrum of antifungal activity includes many fungi, including yeasts and dermatophytes.263 a Has some in vitro activity against some gram-positive bacteria (e.g., staphylococci, Nocardia) and some protozoa (e.g., Acanthamoeba, Leishmania).134 135 136 a
Candida: Active in vitro and in vivo against C. albicans,120 121 122 123 124 373 C. dubliniensis,283 and some strains of C. glabrata,120 122 123 124 373 C. lusitaniae,289 C. parapsilosis,373 and C. tropicalis.373
Other fungi: Active against Blastomyces dermatitidis,263 371 Coccidioides immitis,263 Cryptococcus neoformans,263 373 Histoplasma capsulatum,263 Paracoccidioides brasiliensis,263 and Phialophoa.263 Also active against Actinomadura madurae, Aspergillus flavus,120 122 124 A. fumigatus,122 124 Malassezia furfur (Pityrosporum orbiculare),a Petriellidium boydii,120 122 and Sporothrix schenckii.120 122 124 May be active against some strains of Exophiala castellanii275 and Scopulariopsis, including some strains of S. acremonium and S. brevicaulis.374
Ketoconazole-resistant Candida may be cross-resistant to other azole antifungals (e.g., fluconazole, itraconazole).337
In vitro and in vivo studies indicate ketoconazole can directly inhibit synthesis of adrenal steroids and testosterone.109 110 112 113 114 115 116 117 148 151 154 156 157 158 159 160 161 171 172 173 174 175 176 Appears to inhibit steroid synthesis principally by blocking several P-450 enzyme systems (e.g., 11β-hydroxylase, C-17,20-lyase, cholesterol side-chain cleavage enzyme).112 114 117 151 152 154 155 157 158 159 171 172 173 174 175 176 192 201
Inhibits cortisol synthesis in a dose-dependent manner in individuals with normal adrenocortical function and in patients with Cushing’s syndrome (hypercortisolism).109 112 113 114 151 154 156 157 158 159 166 173 192
Advice to Patients
Importance of taking drugs that may affect gastric acidity, including antacids, histamine H2-receptor antagonists (e.g., cimetidine, ranitidine), and sucralfate, at least 2 hours after ketoconazole.263
Advise patients with achlorhydria to dissolve each 200-mg ketoconazole tablet in 4 mL of 0.2N hydrochloric acid solution.263 Importance of ingesting the solution via a plastic or glass straw to avoid contact with the teeth and importance of drinking a glass of water immediately after the solution.263
Inform patients of the risk of hepatotoxicity and instruct them to report any signs or symptoms of possible hepatic dysfunction (e.g., unusual fatigue, anorexia, nausea and/or vomiting, jaundice, dark urine, pale feces) to their clinician.167 168 188 189 263
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.263
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.263
Importance of advising patients of other important precautionary information.263 (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Ketoconazole Tablets (scored)
aaiPharma, Mutual, Mylan, Pliva, Stada, Taro, Teva, Torpharm
Nizoral (with povidone; scored)
This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 02/2014. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.
Ketoconazole 200MG Tablets (TARO): 14/$30.99 or 42/$88.99
Nizoral 200MG Tablets (JANSSEN): 30/$129.99 or 90/$369.95
AHFS DI Essentials. © Copyright, 2004-2014, Selected Revisions December 1, 2009. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
Only references cited for selected revisions after 1984 are available electronically.
50. Heiberg JK, Svejgaard E. Toxic hepatitis during ketoconazole treatment. BMJ. 1981; 283:825-6. [IDIS 138588] [PubMed 6271328]
61. Firebrace DAJ. Hepatitis and ketoconazole therapy. BMJ. 1981; 283:1058-9. [IDIS 139321] [PubMed 6271330]
101. Craven PC, Graybill JR, Jorgensen JH et al. High-dose ketoconazole for treatment of fungal infections of the central nervous system. Ann Intern Med. 1983; 98:160-7. [IDIS 164926] [PubMed 6297345]
102. van Dijke CPH, Veerman FR, Haverkamp HCH. Anaphylactic reactions to ketoconazole. BMJ. 1983; 287:1673.
103. Meunier-Carpentier F. Chemoprophylaxis of fungal infections. Am J Med. 1984; 76:652-6. [IDIS 183885] [PubMed 6324589]
104. Jones PG, Kauffman CA, McAuliffe LS et al. Efficacy of ketoconazole v nystatin in prevention of fungal infections in neutropenic patients. Arch Intern Med. 1984; 144:549-51. [IDIS 182148] [PubMed 6322710]
105. Meunier-Carpentier F. Treatment of mycoses in cancer patients. Am J Med. 1983; 74(Suppl.):74-9. [IDIS 165059] [PubMed 6295156]
106. Trachtenberg J, Pont A. Ketoconazole therapy for advanced prostate cancer. Lancet. 1984; 2:433-5. [IDIS 189398] [PubMed 6147504]
107. Allen JM, Kerle DJ, Ware H et al. Combined treatment with ketoconazole and luteinising hormone releasing hormone analogue: a novel approach to resistant progressive prostatic cancer. BMJ. 1983; 287:1766. [IDIS 179861] [PubMed 6315133]
108. Williams G. Ketoconazole for prostate cancer. Lancet. 1984; 2:696. [IDIS 190420] [PubMed 6147719]
109. Pont A, Graybill JR, Craven PC et al. High-dose ketoconazole therapy and adrenal and testicular function in humans. Arch Intern Med. 1984; 144:2150-3. [IDIS 192651] [PubMed 6093722]
110. Pont A, Williams PL, Azhar S et al. Ketoconazole blocks testosterone synthesis. Arch Intern Med. 1982; 142:2137-40. [IDIS 160960] [PubMed 6291475]
111. Engelhard D, Stutman HR, Marks MI. Interaction of ketoconazole with rifampin and isoniazid. N Engl J Med. 1984; 311:1681-3. [IDIS 194105] [PubMed 6095080]
112. Stevens DA. Ketoconazole metamorphosis: an antimicrobial becomes an endocrine drug. Arch Intern Med. 1985; 145:813-5. [PubMed 3994459]
113. Sheperd FA, Hoffert B, Evans WK et al. Ketoconazole: use in the treatment of ectopic adrenocorticotropic hormone production and Cushing’s syndrome in small-cell lung cancer. Arch Intern Med. 1985; 145:863-4. [IDIS 199179] [PubMed 2986567]
114. Angeli A, Frairia R. Ketoconazole therapy in Cushing’s disease. Lancet. 1985; 1:821. [IDIS 198857] [PubMed 2858699]
115. Carvalho D, Pignatelli D, Resende C. Ketoconazole for hirsutism. Lancet. 1985; 2:560. [IDIS 204625] [PubMed 2863584]
116. Holland FJ, Fishman L, Bailey JD et al. Ketoconazole in the management of precocious puberty not responsive to LHRH-analogue therapy. N Engl J Med. 1985; 312:1023-8. [IDIS 198728] [PubMed 2984563]
117. Pont A, Goldman ES, Sugar AM et al. Ketoconazole-induced increase in estradiol-testosterone ratio: probable explanation for gynecomastia. Arch Intern Med. 1985; 145:1429-31. [IDIS 202894] [PubMed 4040740]
118. Pottage JC, Kessler HA, Goodrich JM et al. In vitro activity of ketoconazole against herpes simplex virus. Antimicrob Agents Chemother. 1986; 30:215-9. [IDIS 220405] [PubMed 3021048]
119. Minagawa H, Kitaura K, Nakamizo N. Effects of pH on the activity of ketoconazole against Candida albicans. Antimicrob Agents Chemother. 1983; 23:105-7. [IDIS 164455] [PubMed 6299178]
120. Shadomy S, Espinel-Ingroff A, Kerkering TM. In-vitro studies with four new antifungal agents: BAY n7133, bifonazole (BAY h 4502), ICI 153,066 and Ro 14-4767/002. Sabouraudia. 1984; 22:7-15. [PubMed 6322364]
121. Lefler E, Stevens DA. Inhibition and killing of Candida albicans in vitro by five imidazoles in clinical use. Antimicrob Agents Chemother. 1984; 25:450-4. [IDIS 184277] [PubMed 6375555]
122. Espinel-Ingroff A, Shadomy S, Gebhart RJ. In vitro studies with R 51,211 (itraconazole). Antimicrob Agents Chemother. 1984; 26:5-9. [IDIS 187623] [PubMed 6089654]
123. Bergan T, Vangdal M. In vitro activity of antifungal agents against yeast species. Chemotherapy. 1983; 29:104-10. [IDIS 169053] [PubMed 6301773]
124. Gebhart RJ, Espinel-Ingroff A, Shadomy S. In vitro susceptibility studies with oxiconazole (Ro 13-8996). Chemotherapy. 1984; 30:244-7. [IDIS 187989] [PubMed 6086246]
125. Tavitian A, Raufman JP, Rosenthal LE et al. Ketoconazole-resistant Candida esophagitis in patients with acquired immunodeficiency syndrome. Gastroenterology. 1986; 90:443-5. [IDIS 210426] [PubMed 3510145]
126. Ryley JF, Wilson RG, Barrett-Bee KJ. Azole resistance in Candida albicans. Sabouraudia. 1984; 22:53-63. [PubMed 6322363]
127. Thomas AH. Suggested mechanisms for the antimycotic activity of the polyene antibiotics and the N-substituted imidazoles. J Antimicrob Chemother. 1986; 17:269-79. [PubMed 3516967]
128. Sud IJ, Feingold DS. Mechanisms of action of the antimycotic imidazoles. J Invest Dermatol. 1981; 76:438-41. [IDIS 133194] [PubMed 7017013]
129. Pye GW, Marriott MS. Inhibition of sterol C14 demethylation by imidazole-containing antifungals. Sabouraudia. 1982; 20:325-9. [PubMed 6760419]
130. Beggs WH, Andrews FA, Sarosi GA. Minireview: action of imidazole-containing antifungal drugs. Life Sci. 1981; 28:111-8. [PubMed 7019609]
131. Beggs WH. Growth phase in relation to ketoconazole and miconazole susceptibilities of Candida albicans. Antimicrob Agents Chemother. 1984; 25:316-8. [PubMed 6326664]
132. Beggs WH. Influence of growth phase on the susceptibility of Candida albicans to butoconazole, oxiconazole, and sulconazole. J Antimicrob Chemother. 1985; 16:397-9. [PubMed 3902762]
133. Van den Bossche H, Ruysschaert JM, Defrise-Quertain F et al. The interaction of miconazole and ketoconazole with lipids. Biochem Pharmacol. 1982; 31:2609-17. [PubMed 6291539]
134. Samples JR, Binder PS, Luibel FJ et al. Acanthamoeba keratitis possibly acquired from a hot tub. Arch Ophthalmol. 1984; 102:707-10. [PubMed 6372764]
135. Scully RE, Mark EJ, McNeely BU et al. Case records of the Massachusetts General Hospital: case 10-1985. N Engl J Med. 1985; 312:634-41. [PubMed 3883164]
136. Theodore FH, Jakobiec FA, Juechter KB et al. The diagnostic value of a ring infiltrate in Acanthamoebic keratitis. Ophthalmology. 1985; 92:1471-9. [PubMed 4080321]
137. Hirst LW, Green WR, Merz W et al. Management of Acanthamoeba keratitis: a case report and review of the literature. Ophthalmology. 1984; 91:1105-11. [PubMed 6093021]
138. Anon. Acanthamoeba keratitis associated with contact lenses—United States. MMWR Morb Mortal Wkly Rep. 1986; 35:405-8. [PubMed 3088418]
139. Cohen EJ, Buchanan HW, Laughrea PA et al. Diagnosis and management of Acanthamoeba keratitis. Am J Ophthalmol. 1985; 100:389-95. [IDIS 206426] [PubMed 4037025]
140. Moore MB, McCulley JP, Luckenbach M et al. Acanthamoeba keratitis associated with soft contact lenses. Am J Ophthalmol. 1985; 100:396-403. [IDIS 206427] [PubMed 3898851]
141. Doble N, Hykin P, Shaw R et al. Pulmonary Mycobacterium tuberculosis in acquired immune deficiency syndrome. BMJ. 1985; 291:849-50. [IDIS 205189] [PubMed 3931740]
142. Ferguson RM, Sutherland DER, Simmons RL et al. Ketoconazole, cyclosporin metabolism, and renal transplantation. Lancet. 1982; 2:882-3. [IDIS 158221] [PubMed 6126744]
143. Dieperink H, Moller J. Ketoconazole and cyclosporin. Lancet. 1982; 2:1217. [IDIS 161092] [PubMed 6128518]
144. Shepard JH, Canafax DM, Simmons RL et al. Cyclosporine-ketoconazole: a potentially dangerous drug-drug interaction. Clin Pharm. 1986; 5:468. [IDIS 216399] [PubMed 3720214]
145. Daneshmend TK. Ketoconazole-cyclosporin interaction. Lancet. 1982; 2:1342-3. [IDIS 161858] [PubMed 6128627]
146. Hansten PD, Horn JR. Ketoconazole (Nizoral) interactions. Drug Interact Newsl. 1986; 6(Updates):U19-20.
147. Murphy E, Hannon D, Callaghan B. Ketoconazole-theophylline interaction. Ir Med J. 1987; 80:123-4. [PubMed 3597030]
148. National Committe for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NCCLS document M27-A. Wayne, PA: NCCLS; 1997 Jun.
149. Huang YC, Colaizzi JL, Bierman RH et al. Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. Antimicrob Agents Chemother. 1986; 30:206-10. [IDIS 220403] [PubMed 3767339]
150. Brown MW, Maldonado AL, Meredith CG et al. Effect of ketoconazole on hepatic oxidative drug metabolism. Clin Pharmacol Ther. 1985; 37:290-7. [IDIS 197455] [PubMed 3971653]
151. Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med. 1987; 317:812-8. [IDIS 233977] [PubMed 3306384]
152. Litt MR, Bell WR, Lepor HA. Disseminated intravascular coagulation in prostatic carcinoma reversed by ketoconazole. JAMA. 1987; 258:1361-2. [IDIS 233299] [PubMed 3625935]
153. Umstead GS, Babiak LM, Tejwani S. Immune hemolytic anemia associated with ketoconazole therapy. Clin Pharm. 1987; 6:499-500. [IDIS 230326] [PubMed 3690997]
154. Loli P, Berselli ME, Tagliaferri M. Use of ketoconazole in the treatment of Cushing’s syndrome. J Clin Endocrinol Metab. 1986; 63:1365-71. [IDIS 225322] [PubMed 3023421]
155. Lamberts SWJ, Bons EG, Bruining HA et al. Differential effects of the imidazole derivatives etomidate, ketoconazole and miconazole and of metyrapone on the secretion of cortisol and its precursors by human adrenocortical cells. J Pharmacol Exp Ther. 1987; 240:259-64. [PubMed 3027305]
156. Pont A, Williams PL, Loose DS et al. Ketoconazole blocks adrenal steroid synthesis. Ann Intern Med. 1982; 97:370-2. [IDIS 156077] [PubMed 6287893]
157. Tucker WS Jr, Snell BB, Island DP et al. Reversible adrenal insufficiency induced by ketoconazole. JAMA. 1985; 253:2413-4. [IDIS 198754] [PubMed 3981770]
158. Howden CW. Effect of ketoconazole on the synthesis of cortisol. J Infect Dis. 1986; 153:378. [IDIS 211056] [PubMed 3944491]
159. Best TR, Jenkins JK, Murphy FY et al. Persistent adrenal insufficiency secondary to low-dose ketoconazole therapy. Am J Med. 1987; 82:676-80. [IDIS 228333] [PubMed 3826130]
160. White MC, Kendall-Taylor P. Adrenal hypofunction in patients taking ketoconazole. Lancet. 1985; 1:44-5. [PubMed 2856964]
161. Pillans PI, Cowan P, Whitelaw D. Hyponatraemia and confusion in a patient taking ketoconazole. Lancet. 1985; 1:821-2. [IDIS 198858] [PubMed 2858700]
162. Clissold SP. Pharmacokinetic properties. In: Jones HE, ed. Ketoconazole today: a review of clinical experience. Manchester, England: ADIS Press Ltd; 1987:19-28.
163. Ginsburg CM, McCracken GH Jr, Olsen K. Pharmacology of ketoconazole suspension in infants and children. Antimicrob Agents Chemother. 1983; 23:787-19. [IDIS 170772] [PubMed 6307138]
164. Lake-Bakaar G, Scheuer PJ, Sherlock S. Hepatic reactions associated with ketoconazole in the United Kingdom. BMJ. 1987; 294:419-22. [IDIS 226772] [PubMed 3101906]
165. Tabor E. Hepatotoxicity of ketoconazole in men and in patients under 50. N Engl J Med. 1987; 316:1606. [IDIS 230809] [PubMed 3587297]
166. McCance DR, Ritchie CM, Sheridan B et al. Acute hypoadrenalism after treatment with ketoconazole. Lancet. 1987; 1:573. [IDIS 226810] [PubMed 2881126]
167. Lewis JH, Zimmerman HJ, Benson GD et al. Hepatic injury associated with ketoconazole therapy. Gastroenterology. 1984; 86:503-13. [IDIS 181840] [PubMed 6319220]
168. Duarte PA, Chow CC, Simmons F et al. Fatal hepatitis associated with ketoconazole therapy. Arch Intern Med. 1984; 144:1069-70. [IDIS 184764] [PubMed 6324708]
169. Bercoff E, Bernuau J, Degott C et al. Ketoconazole-induced fulminant hepatitis. Gut. 1985; 26:636-8. [IDIS 203609] [PubMed 4007605]
170. Dismukes WE, Stamm AM, Graybill JR et al. Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. Ann Intern Med. 1983; 98:13-20. [IDIS 162785] [PubMed 6293361]
171. Kowal J. The effect of ketoconazole on steroidogenesis in cultured mouse adrenal cortex tumor cells. Endocrinology. 1983; 112:1541-3. [PubMed 6299699]
172. Loose DS, Kan PB, Hirst MA et al. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest. 1983; 71:1495-9. [PubMed 6304148]
173. Engelhardt D, Dorr G, Jaspers C et al. Ketoconazole blocks cortisol secretion in man by inhibition of adrenal 11β-hydroxylase. Klin Wochenschr. 1985; 63:607-12. [PubMed 2993735]
174. Santen RJ, Van den Bossche H, Symoens J et al. Site of action of low dose ketoconazole on androgen biosynthesis in men. J Clin Endocrinol Metab. 1983; 57:732-6. [IDIS 176459] [PubMed 6309882]
175. Kan PB, Hirst MA, Feldman D. Inhibition of steroidogenic cytochrome P-450 enzymes in rat testis by ketoconazole and related imidazole anti-fungal drugs. J Steroid Biochem. 1985; 23:1023-9. [PubMed 3841572]
176. Nagai K, Miyamori I, Ikeda M et al. Effect of ketoconazole (an imidazole antimycotic agent) and other inhibitors of steroidogenesis on cytochrome P450-catalyzed reactions. J Steroid Biochem. 1986; 24:321-3. [PubMed 3702414]
177. Baxter JG, Brass C, Schentag JJ et al. Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs. J Pharm Sci. 1986; 75:443-7. [IDIS 216962] [PubMed 3735080]
178. Lowe FC, Somers WJ. The use of ketoconazole in the emergency management disseminated intravascular coagulation due to metastatic prostatic cancer. J Urol. 1987; 137:1000-2. [IDIS 229184] [PubMed 3573156]
179. Nicolle P, Pontin A, Sarembock L. High-dose ketoconazole therapy in prostatic cancer: a pilot study. S Afr Med J. 1985; 67:888-9. [IDIS 205320] [PubMed 4002070]
180. Trachtenberg J. Ketoconazole therapy in advanced prostatic cancer. J Urol. 1984; 132:61-3. [IDIS 187226] [PubMed 6328052]
181. Williams G, Kerle DJ, Ware H et al. Objective responses to ketoconazole therapy in patients with relapsed progressive prostatic cancer. Br J Urol. 1986; 58:45-51. [PubMed 3947856]
182. Vanuytsel L, Ang KK, Vantongelen K et al. Ketoconazole therapy for advanced prostatic cancer: feasibility and treatment results. J Urol. 1987; 137:905-8. [IDIS 229179] [PubMed 2952808]
183. Pont A. Long-term experience with high dose ketoconazole therapy in patients with stage D2 prostatic carcinoma. J Urol. 1987; 137:902-4. [IDIS 229178] [PubMed 2437334]
184. Trachtenberg J. Ketoconazole therapy in advanced prostatic cancer. J Urol. 1987; 137:959. [IDIS 229182] [PubMed 3573195]
185. Holland FJ, Kirsch SE, Selby R. Gonadotropin-independent precocious puberty (“testotoxicosis:): influence of maturational status on response to ketoconazole. J Clin Endocrinol Metab. 1987; 64:328-33. [IDIS 225669] [PubMed 3539979]
186. Root AW, Zamanillo J, Duckett G et al. Gondadotropin-independent isosexual precocity in a boy with tuberous sclerosis: effect of ketoconazole. J Pediatr. 1986; 109:1012-5. [IDIS 224967] [PubMed 3097292]
187. Singhal T, Bajpai A, Kalra V et al. Successful treatment of Acanthamoeba meningitis with combination oral antimicrobials. Ped Infect Dis J. 2001; 20:623-7.
188. Svejgaard E, Ranek L. Hepatic dysfunction and ketoconazole therapy. Ann Intern Med. 1982; 96(6 Part 1):788-9. [IDIS 152654] [PubMed 6283980]
189. Tkach JR, Rinaldi MG. Severe hepatitis associated with ketoconazole therapy for chronic mucocutaneous candidiasis. Cutis. 1982; 29:482-3. [PubMed 6284445]
190. Rollman O, Lööf L. Hepatic toxicity of ketoconazole. Br J Dermatol. 1983; 108:376-8. [IDIS 168054] [PubMed 6299322]
191. Janssen PAJ, Symoens JE. Hepatic reactions during ketoconazole treatment. Am J Med. 1983; 74(Suppl):80-5. [IDIS 165060] [PubMed 6129799]
192. Clissold SP. Safety in clinical practice. In: Jones HE, ed. Ketoconazole today: a review of clinical experience. Manchester, England: ADIS Press Ltd; 1987:77-89.
193. Boughton K. Ketoconazole and hepatic reactions. S Afr Med J. 1983; 63:955. [IDIS 174106] [PubMed 6304923]
194. Meurice JC, Lecomte P, Renard JP et al. Interaction miconazole et sulfamides hypoglycémiants. Presse Med. 1983; 18:1670.
195. Astohova AV. Miconazole. In: Dukes MNG, ed. Side effects of drugs. Annual 8. New York: Elsevier Science Publishing Co, Inc; 1984:270.
196. Marcon MJ, Durrell DE, Powell DA et al. In vitro activity of systemic antifungal agents against Malassezia furfur. Antimicrob Agents Chemother. 1987; 31:951-3. [IDIS 232046] [PubMed 3619430]
197. Loupi E, Descotes J, Lery N et al. Interactions médicamenteuses et miconazole: a propos de 10 observations. Thérapie. 1982; 37:437-41.
198. Lake-Bakaar G, Tom W, Lake-Bakaar D et al. Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1988; 109:471-3. [IDIS 245862] [PubMed 3415107]
199. Lelawongs P, Barone JA, Colaizzi JL et al. Effect of food and gastric acidity on absorption of orally administered ketoconazole. Clin Pharm. 1988; 7:228-35. [IDIS 239224] [PubMed 3356120]
200. Lake-Bakaar G, Beidas S, El-Sakir R et al. Impaired gastric acid secretion in AIDS. Gastroenterology. 1987; 92:1488.
201. Aabo K, De Coster R. Hypertension during high-dose ketoconazole treatment: a probable mineralocorticosteroid effect. Lancet. 1987; 2:637-8. [IDIS 233788] [PubMed 2887934]
202. Pfaller A, Rex JH, Rinaldi MG. Antifungal susceptibility testing: technical advances and potential clinical applications. Clin Infect Dis. 1997; 24:776-84. [IDIS 386039] [PubMed 9142769]
203. Viallet J, MacLean DJ, Robson H. Response to ketoconazole in two cases of longstanding cutaneous leishmaniasis. Am J Trop Med Hyg. 1986; 35:491-5. [PubMed 3706620]
204. Chaniotis BN, Johnson CM, Christensen HA et al. Acquisition, development, and treatment of Panamanian cutaneous leishmaniasis: a case history. Mil Med. 1988; 153:405-6. [IDIS 245000] [PubMed 3140056]
205. Weinrauch L, El-On J. The effect of ketoconazole and a combination of rifampicin/amphotericin B on cutaneous leishmaniasis in laboratory mice. Trans R Soc Trop Med Hyg. 1984; 78:389-90. [PubMed 6087514]
206. Weinrauch L, Livshin R, Jacobs GP et al. Cutaneous leishmaniasis: failure of topical treatment with imidazole derivatives in laboratory animals and man. Arch Dermatol Res. 1984; 276:133-4. [PubMed 6326697]
207. Weinrauch L, Livshin R, Even-Paz Z et al. Efficacy of ketoconazole in cutaneous leishmaniasis. Arch Dermatol Res. 1983; 275:353-4. [PubMed 6318670]
208. Weinrauch L, Livshin R, El-On J. Cutaneous leishmaniasis: treatment with ketoconazole. Cutis. 1983; 32:288-9,294. [PubMed 6313298]
209. Urcuyo FG, Zaias N. Oral ketoconazole in the treatment of leishmaniasis. Int J Dermatol. 1982; 21:414-6. [PubMed 6290403]
210. Urcuyo FG, Zaias N. The successful treatment of pityriasis versicolor by systemic ketoconazole. J Am Acad Dermatol. 1982; 6:24-5. [PubMed 6282946]
211. Pitrak DL, Andersen BR. Cerebral blastomycoma after ketoconazole therapy for respiratory tract blastomycosis. Am J Med. 1989; 86:713-4. [IDIS 255557] [PubMed 2729325]
212. National Institutes of Health. Consensus development conference statement: oral complications of cancer therapies: diagnosis, prevention, and treatment. 1989; 7(7):1-12.
213. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Treatment of blastomycosis and histoplasmosis with ketoconazole: results of a prospective randomized clinical trial. Ann Intern Med. 1985; 103:(6 Part 1):861-72.
214. Galgiani JN, Stevens DA, Graybill JR et al. Ketoconazole therapy for progressive coccidioidomycosis: comparison of 400- and 800-mg doses and observations at higher doses. Am J Med. 1988; 84:603-10. [IDIS 240450] [PubMed 3279775]
215. Hebert CA, King JW, George RB. Late dissemination of pulmonary blastomycosis during ketoconazole therapy. Chest. 1989; 95:240-2. [IDIS 301628] [PubMed 2909344]
216. Greene NB, Baughman RP, Kim CK et al. Failure of ketoconazole in an immunosuppressed patient with pulmonary blastomycosis. Chest. 1985; 88:640-1. [IDIS 207498] [PubMed 3899536]
217. Thiele JS, Buechner HA, Cook EW Jr. Failure of ketoconazole in two patients with blastomycosis. Chest. 1985; 88:640-1. [IDIS 207498] [PubMed 3899536]
218. McManus EJ, Jones JM. The use of ketoconazole in the treatment of blastomycosis. Am Rev Respir Dis. 1986; 133:141-3. [IDIS 211606] [PubMed 3942371]
219. Sugar AM. Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob Agents Chemother. 1995; 39:1907-12.
220. Bradsher RW, Rice DC, Abernathy RS. Ketoconazole therapy for endemic blastomycosis. Ann Intern Med. 1983; 103(6 Part 1):872-9.
221. Abadie-Kemmerly S, Pankey GA, Dalovisio JR. Failure of ketoconazole treatment of Blastomyces dermatitidis due to interaction of isoniazid and rifampin. Ann Intern Med. 1988; 109:844-5. [IDIS 248041] [PubMed 3190036]
222. Holmes B, Brogden RN, Richards DM. Norfloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1985; 30:482-513. [IDIS 209686] [PubMed 3908074]
223. Overbeek BP, Rozenberg-Arska M, Verhoef J. Do quinolones really augment the antifungal effect of amphotericin B in vitro? Drugs Exp Clin Res. 1985; 11:745-6.
224. Farwell AP, Devlin JT, Stewart JA. Total suppression of cortisol excretion by ketoconazole in the therapy of the ectopic adrenocorticotropic hormone syndrome. Am J Med. 1988; 84:1063-6. [IDIS 242041] [PubMed 3376976]
225. Anon. Drugs for parasitic infections. Med Lett Drugs Ther. Apr 2002. From the Medical Letter website.
226. Yeung EY, Huang SC, Tsai RJ. Acanthamoeba keratitis presenting as dendritic keratitis in a soft contact lens wearer. Chang Gung Med J. 2002; 25:201-6. [PubMed 12022742]
227. Glynn AM, Slaughter RL, Brass C et al. Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion. Clin Pharmacol Ther. 1986; 39:654-9. [IDIS 217705] [PubMed 3709030]
228. Kandrotas RJ, Slaughter RL, Corstiaan B et al. Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol. Clin Pharmacol Ther. 1987; 42:465-70. [IDIS 234787] [PubMed 3311551]
229. Khosla S, Wolfson JS, Demerjian Z et al. Adrenal crisis in the setting of high-dose ketoconazole therapy. Arch Int Med. 1989; 149:802-4.
230. Britton H, Shehab Z, Lightner E et al. Adrenal response in children receiving high doses of ketoconazole for systemic coccidioidomycosis. J Pediatr. 1988; 112:488-92. [IDIS 239538] [PubMed 2831330]
231. Monahan BP, Ferguson CL, Killeavy ES et al. Torsades de pointes occurring in association with terfenadine use. JAMA. 1990; 264:2788-90. [IDIS 274495] [PubMed 1977935]
232. Zurcher RM, Frey BM, Frey FJ. Impact of ketoconazole on the metabolism of prednisolone. Clin Pharmacol Ther. 1989; 45:366-72. [IDIS 253522] [PubMed 2639662]
233. Corticosteroids/ketoconazole. In: Tatro DS, Olin BR, eds. Drug interaction facts. St. Louis; JB Lippincott Co; 1990 (October):220.
234. Committee on Infectious Diseases, American Academy of Pediatrics. 2000 Red book: report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2000:189-90,198-201,219-21,365-7,574-6,668-72.
235. Saag MS, Dismukes WE. Treatment of histoplasmosis and blastomycosis. Chest. 1988; 93:848-51. [IDIS 311626] [PubMed 3280262]
236. Bradsher RW. Blastomycosis: fungal infections of the lung update: 1989. Semin Respir Infect. 1990; 5:105-10. [PubMed 2247705]
237. Davies SF, Sarosi GA. Blastomycosis. Eur J Clin Microbiol Infect Dis. 1989; 8:474-9. [PubMed 2502412]
238. Anon. Systemic antifungal drugs. Med Lett Drugs Ther. 1997; 39:85-8. [PubMed 9305291]
239. Murphy PA. Blastomycosis. JAMA. 1989; 261:3159-62. [IDIS 254594] [PubMed 2716144]
240. Salem HT, Salah M, Farid A et al. Oral versus local treatment of vaginal candidosis. Int J Gynaecol Obstet. 1989; 30:57-62. [PubMed 2572475]
241. van der Meijden WI, van der Hoek JC, Staal HJ et al. Double-blind comparison of 200-mg ketoconazole oral tablets and 1200-mg miconazole vaginal capsule in the treatment of vaginal candidosis. Eur J Obstet Gynecol Reprod Biol. 1986; 22:133-8. [PubMed 3525273]
242. Puolakka J, Tuimala R. Comparison between oral ketoconazole and topical miconazole in the treatment of vaginal candidiasis. Acta Obstet Gynecol Scand. 1983; 62:575-7. [PubMed 6322505]
243. Miller PI, Humphries M, Grassick K. A single-blind comparison of oral and intravaginal treatments in acute and recurrent vaginal candidosis in general practice. Pharmatherapeutica. 1984; 3:582-7. [PubMed 6328542]
244. Bingham JS. Single blind comparison of ketoconazole 200 mg oral tablets and clotrimazole 100 mg vaginal tablets and 1% cream in treating acute vaginal candidosis. Br J Vener Dis. 1984; 60:175-7. [PubMed 6329405]
245. Benhamou E, Hartmann O, Nogues C et al. Does ketoconazole prevent fungal infection in children treated with high dose chemotherapy and bone marrow transplantation? Results of a randomized placebo-controlled trial. Bone Marrow Transplant. 1991; 7:127-31. [PubMed 2049556]
246. Shepp DH, Klosterman A, Siegel MS et al. Comparative trial of ketoconazole and nystatin for prevention of fungal infection in neutropenic patients treated in a protective environment. J Infect Dis. 1985; 152:1257-63. [IDIS 209089] [PubMed 3905986]
247. Turhan A, Connors JM, Klimo P. Ketoconazole versus nystatin as prophylaxis against fungal infection for lymphoma patients receiving chemotherapy. Am J Clin Oncol. 1987; 10:355-9. [PubMed 2441593]
248. Vogler WR, Malcom LG, Winton EF. A randomized trial comparing ketoconazole and nystatin prophylactic therapy in neutropenic patients. Cancer Invest. 1987; 5:267-73. [PubMed 3664330]
249. Walsh TJ, Rubin M, Hathorn J et al. Amphotericin B vs high-dose ketoconazole for empirical antifungal therapy among febrile, granulocytopenic cancer patients: a prospective, randomized study. Arch Intern Med. 1991; 151:765-70. [IDIS 280492] [PubMed 2012462]
250. Saenz RE, Paz H, Berman JD. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am J Med. 1990; 89:147-55. [IDIS 270063] [PubMed 2166429]
251. Piscitelli SC, Goss TF, Wilton JH et al. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother. 1991; 35:1765-71. [IDIS 287975] [PubMed 1952845]
252. Marion Merrell Dow Seldane (terfenadine) tablets prescribing information. Kansas City, MO: 1992 Sep.
253. Marion Merrell Dow, Kansas City, MO: Personal communication.
254. Cruzan S (US Food and Drug Administration). HHS News. Press release No. P92-22. 1992 Jul 7.
255. Marion Merrell Dow. Dear health care professional letter regarding appropriate use of Seldane. Kansas City, MO: July 7, 1992.
256. Zimmerman M, Duruz H, Guinand O et al. Torsades de pointes after treatment with terfenadine and ketoconazole. Eur Heart J. 1992; 13:1002-3. [PubMed 1644069]
257. Mathews DR, McNutt B, Okerholm R et al. Torsades de pointes occurring in association with terfenadine use. JAMA. 1991; 266:2375-6. [IDIS 287469] [PubMed 1920744]
258. Cortese L, Bjornson DC. Potential interaction between terfenadine and macrolide antibiotics. Clin Pharm. 1992; 11:675. [IDIS 299287] [PubMed 1511540]
259. Cantilena LR Jr, Ferguson CL. Torsades de pointes occurring in association with terfenadine use. JAMA. 1991; 266:2376.
260. Eller MG, Okerholm RA. Pharmacokinetic interaction between terfenadine and ketoconazole. Clin Pharmacol Ther. 1991; 49:130.
261. Wali JP, Aggarwal P, Gupta U et al. Ketoconazole in treatment of visceral leishmaniasis. Lancet. 1990; 336:810-1. [IDIS 272210] [PubMed 1976166]
262. Sundar S, Kumar K, Singh VP. Ketoconazole in visceral leishmaniasis. Lancet. 1990; 336:1582-3. [IDIS 275614] [PubMed 1979393]
263. Janssen Pharmaceutica. Nizoral (ketoconazole) tablets prescribing information. Titusville, NJ; 1998 Jul.
264. Chapman SW, Bradsher RW, Campbell GD et al. Practice guidelines for the management of patients with blastomycosis. Clin Infect Dis. 2000; 30:679-83. [IDIS 448064] [PubMed 10770729]
265. Janssen Pharmaceutica. Hismanal (astemizole) tablets prescribing information. Titusville, NJ; 1998 Feb.
266. Janssen Pharmaceutica, Titusville, NJ: Personal communication.
267. Magnasco AJ, Magnasco LD. Interaction of ketoconazole and ethanol. Clin Pharm. 1986; 5:522-3. [IDIS 216409] [PubMed 2941211]
268. Meyboom RH, Pater BW. [Hypersensitivity to alcoholic beverages during treatment with ketoconazole]. Ned Tijdschr Geneeskd. 1989; 133:1463-4. [PubMed 2797244]
269. Mead Johnson Oncology Products. Taxol (paclitaxel) injection prescribing information. Princeton, NJ; 2000 Jul.
270. Centers for Disease Control and Prevention. Guidelines for treatment of sexually transmitted diseases 2002. MMWR Morb Mortal Wkly Rep. 2002;51(No.RR-6):1-78.
271. Sobel JD. Recurrent vulvovaginal candidiasis: a prospective study of the efficacy of maintenance ketoconazole therapy. N Engl J Med. 1986; 315:1455-8. [IDIS 223207] [PubMed 3537785]
272. Anon. Drugs for sexually transmitted diseases. Med Lett Drugs Ther. 1999; 41:85-90. [PubMed 10906932]
273. Chin TWF, Loeb M, Fong IW. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob Agents Chemother. 1995; 39:1671-5. [IDIS 352188] [PubMed 7486898]
274. Sharma JB, Buckshee K, Gulati N. Oral ketoconazole and miconazole vaginal pessary treatment for vaginal candidosis. Aust N Z J Obstet Gynaecol. 1991; 31:276-8. [PubMed 1804095]
275. Gold WL, Vellend H, Salit IE et al. Successful treatment of systemic and local infections due to Exophiala species. Clin Infect Dis. 1994; 19:339-41. [IDIS 334166] [PubMed 7986913]
276. Klausner MA. Dear Pharmacist letter. Titusville, NJ: Janssen Pharmaceutica; 1995.
277. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther. 1994; 56:601-7. [IDIS 342218] [PubMed 7995001]
278. Greenblatt DJ, von Moltke LL, Harmatz JS et al. Interaction of triazolam and ketoconazole. Lancet. 1995; 345: Letter. [IDIS 341080] [PubMed 7823684]
279. Anon. Drugs for AIDS and associated infections. Med Lett Drugs Ther. 1995; 37:87-94. [PubMed 7565297]
280. Smith GH. Treatment of infections in the patient with acquired immunodeficiency syndrome. Arch Intern Med. 1994; 154:949-73. [IDIS 329350] [PubMed 8179453]
281. American Thoracic Society. Fungal infection in HIV-infected persons. Am J Respir Crit Care Med. 1995; 152:816-22. [IDIS 352046] [PubMed 7633749]
282. US Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA) Prevention of Opportunistic Infections Working Group. 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons with human immunodeficiency virus. From the US Department of Health and Human Services HIV/AIDS Information Services (AIDSinfo) website.
283. Moran GP, Sullivan DJ, Henman MC et al. Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob Agents Chemother. 1997; 41:617-23. [IDIS 383166] [PubMed 9056003]
284. Cersosimo RJ, Carr D. Prostate cancer: current and evolving strategies. Am J Health Syst Pharm. 1996; 53:381-96. [IDIS 360612] [PubMed 8673658]
285. Small EJ, Baron AD, Fippin L et al. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol. 1997; 157:1204-7. [IDIS 383657] [PubMed 9120902]
286. Prostatic cancer. From: PDQ Information for Health Care Professionals (database). Bethesda, MD: National Cancer Institute; 1997 Dec.
287. Honig PK, Wortham DC, Zamani K et al. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA. 1993; 269:1513-8. [IDIS 311126] [PubMed 8445813]
288. Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone Inc; 1995:2300-9,2316-23,2336-8,2350-1,2371,2388-9,2413,2428-36,2714-9.
289. Favel A, Michel-Nguyen A, Chastin C et al. In-vitro susceptibility pattern of Candida lusitaniae and evaluation of the Etest method. J Antimicrob Chemother. 1997; 39:591-6. [IDIS 387158] [PubMed 9184357]
290. Kauffman CA. Role of azoles in antifungal therapy. Clin Infect Dis. 1996; 22(Suppl 2:S148-53. [IDIS 367021] [PubMed 8722843]
291. Reynolds JEF, ed. Martindale: the extra pharmacopoeia. 31st ed. London: The Pharmaceutical Press; 1996:383-402.
292. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med. 1994; 220:263-72.
293. Klein NC, Cunha BA. New antifungal drugs for pulmonary mycoses. Chest. 1996; 110:525-32. [IDIS 371846] [PubMed 8697859]
294. Armstrong D. Treatment of opportunistic fungal infections. Clin Infect Dis. 1993; 16:1-9. [IDIS 307821] [PubMed 8448281]
295. Yancey RW, Perlino CA, Kaufman L. Asymptomatic blastomycosis of the central nervous system with progression in patients given ketoconazole therapy: a report of two cases. J Infect Dis. 1991; 164:807-10. [IDIS 289561] [PubMed 1894941]
296. Pappas PG, Pottage JC, Powderly WG et al. Blastomycosis in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1992; 116:847-53. [IDIS 296295] [PubMed 1567099]
297. Mangino JE, Pappas PG. Itraconazole for the treatment of histoplasmosis and blastomycosis. Int J Antimicrob Agents. 1995; 5:219-25. [PubMed 18611672]
298. Chao D, Steier KJ, Gomila R. Update and review of blastomycosis. J Am Osteopath Assoc. 1997; 97:525-32. [PubMed 9313349]
299. Bradsher RW. Therapy of blastomycosis. Semin Respir Infect. 1997; 12:263-7. [PubMed 9313298]
300. Varkey B. Blastomycosis in children. Semin Respir Infect. 1997; 12:235-42. [PubMed 9313295]
301. Chapman SW, Lin AC, Hendricks KA et al. Endemic blastomycosis in Mississippi: epidemiological and clinical studies. Semin Respir Infect. 1997; 12:219-28. [PubMed 9313293]
302. Pappagianis D. Coccidioidomycosis. Semin Dermatol. 1993; 12:301-9. [PubMed 8312146]
303. Galgiani JN, Ampel NM. Coccidioidomycosis in human immunodeficiency virus—infected patients. J Infect Dis. 1990; 162:1165-9. [IDIS 274447] [PubMed 2230241]
304. Ross JB, Levine B, Catanzaro A et al. Ketoconazole for treatment of chronic pulmonary coccidioidomycosis. Ann Intern Med. 1982; 96:440-3. [IDIS 147424] [PubMed 6279005]
305. Catanzaro A, Einstein H, Levine B et al. Ketoconazole for treatment of disseminated coccidioidomycosis. Ann Intern Med. 1982; 96:436-40. [IDIS 147423] [PubMed 6279004]
306. Perfect JR, Durack DT, Hamilton JD et al. Failure of ketoconazole in cryptococcal meningitis. JAMA. 1982; 247:3349-51. [IDIS 151469] [PubMed 6283185]
307. Powderly WG. Recent advances in the management of cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1996; 22(Suppl 2):S119-23.
308. Van der Horst CM, Saag MS, Cloud GA et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med. 1997; 337:15-21. [IDIS 387972] [PubMed 9203426]
309. Quinones CA, Reuben AG, Hamill RJ et al. Chronic cavitary histoplasmosis: failure of oral treatment with ketoconazole. Chest. 1989; 95:914-6. [IDIS 305630] [PubMed 2924624]
310. Goldani LZ, Sugar A. Paracoccidioidomycosis and AIDS: an overview. Clin Infect Dis. 1995; 21:1275-81. [IDIS 356544] [PubMed 8589154]
311. Nishioka S. Paracoccidioidomycosis and AIDS. Clin Infect Dis. 1996; 22:1132. [IDIS 368827] [PubMed 8783743]
312. Kauffman CA. Old and new therapies for sporotrichosis. Clin Infect Dis. 1995; 21:981-5. [IDIS 355567] [PubMed 8645851]
313. Dall L, Salzman G. Treatment of pulmonary sporotrichosis with ketoconazole. Rev Infect Dis. 1987; 9:795-8. [IDIS 232257] [PubMed 3326126]
314. Baum KF, Berens RL. Successful treatment of cutaneous Leishmaniasis with allopurinol after failure of treatment with ketoconazole. Clin Infect Dis. 1994; 18:813-5. [IDIS 330116] [PubMed 8075279]
315. Wali JP, Aggarwal P, Gupta U et al. Ketoconazole in the treatment of antimony- a pentamidine-resistant Kala-Azar. J Infect Dis. 1992; 166:215-6. [IDIS 298740] [PubMed 1607703]
316. Navin TR, Arana MA, Arana FE et al. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous Leishmaniasis in Guatemala. J Infect Dis. 1992; 165:528-34. [IDIS 292342] [PubMed 1311351]
317. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic development in the last 10 years. Clin Infect Dis. 1997; 24:684-703. [IDIS 384365] [PubMed 9145744]
318. Halim MA, Alfurayh O, Kalin ME et al. Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in a renal transplant recipient after the occurrence of pancreatitis due to stibogluconate. Clin Infect Dis. 1993; 16:397-9. [IDIS 310978] [PubMed 8135901]
319. Despommier DD, Gwadz RW, Hotez PJ. Parasitic Diseases. 3rd ed. New York: Springer-Verlag; 1995:203-9.
320. Hay KD. Candidosis of the oral cavity: recognition and management. Drugs. 1988; 36:633-42. [IDIS 249264] [PubMed 3063501]
321. Hansen RM, Reinerio N, Sohnle PG et al. Ketoconazole in the prevention of candidiasis in patients with cancer: a prospective, randomized, controlled, double-blind study. Arch Intern Med. 1987; 147:710-12. [IDIS 227952] [PubMed 3548626]
322. Weinert M, Grimes RM, Lynch DP. Oral manifestations of HIV infection. Ann Intern Med. 1996; 125:485-96. [PubMed 8779462]
323. Drake LA, Dinehart SM, Farmer ER et al et al. Guidelines of care for superficial mycotic infections of the skin: mucocutaneous candidiasis. J Am Acad Dermatol. 1996; 34:110-5. [IDIS 361417] [PubMed 8543679]
324. Drake LA, Dinehart SM, Farmer ER et al. Guidelines of care for superficial mycotic infections of the skin: pityriasis (tinea) versicolor. J Am Acad Dermatol. 1996; 34:287-9. [IDIS 363963] [PubMed 8642095]
325. Drake LA, Dinehart SM, Farmer ER et al. Guidelines of care for superficial mycotic infections of the skin: tinea capitis and tinea barbae. J Am Acad Dermatol. 1996; 23:290- 4.
326. Hughes WT, Armstrong D, Bodey GP et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis. 1997; 25:551-73. [IDIS 393722] [PubMed 9314442]
327. Galgiani JN, Ampel NM, Catanzaro A et al. Practice guidelines for the treatment of coccidioidomycosis. Clin Infect Dis. 2000; 30:658-61. [IDIS 448062] [PubMed 10770727]
328. Rowe JM, Ciobanu N, Ascensao J et al et al. Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation: a report from the Eastern Cooperative Oncology Group (ECOG). Ann Intern Med. 1994; 120:143-58. [IDIS 323859] [PubMed 8256974]
329. Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis. 1993; 16:677-88. [IDIS 314580] [PubMed 8507760]
330. Saag MS, Graybill RJ, Larsen RA et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis. 2000; 30:710-8. [IDIS 448068] [PubMed 10770733]
331. Edwards JE, Bodey GP, Bowden RA et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis. 1997; 25:43-59. [IDIS 387869] [PubMed 9243032]
332. Pappas PG. Blastomycosis in the immunocompromised patient. Semin Respir Infect. 1997; 12:243-51. [PubMed 9313296]
333. Davies SF, Sarosi GA. Epidemiological and clinical features of pulmonary blastomycosis. Semin Respir Infect. 1997; 12:206-18. [PubMed 9313292]
334. Herrod HG. Chronic mucocutaneous candidiasis in childhood and complications of non-Candidal infection: a report of the Pediatric Immunodeficiency Collaborative Study Group. J Pediatr. 1990; 116:377-82. [PubMed 2308026]
335. Restrepo A. Treatment of tropical mycoses. J Am Acad Dermatol. 1994; 31:S91-102. [IDIS 335778] [PubMed 8077517]
336. Pepose JS, Holland G, Wilhelmus KR. Ocular infections & immunology. St. Louis, MO:Mosby—Year Book Inc; 1996:1048-61,1262-85.
337. Alexander BD, Perfect JR. Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches. Drugs. 1997; 54:657-78. [PubMed 9360056]
338. Klausner MA. Dear doctor letter regarding important drug warning of Hismanal (astemizole). Titusville, NJ: Janssen Pharmaceutica; 1998 Feb.
339. Doering PL, Santiago TM. Drugs for the treatment of vulvovaginal candidiasis: comparative efficacy of agents and regimens. DICP. 1990; 24:1078-83. [IDIS 274670] [PubMed 2275233]
340. Sobel JD. Vaginitis. N Engl J Med. 1997; 337:1896-903. [IDIS 401347] [PubMed 9407158]
341. Rex JH, Walsh TJ, Sobel JD et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis. 2000; 30:662-78. [IDIS 448063] [PubMed 10770728]
342. Berwaerts JJ, Verhelst JA, Verhaert GC et al. Corticotropin-dependent Cushing’s syndrome in older people: presentation of five cases and therapeutical use of ketoconazole. J Am Geriatr Soc. 1998; 46:880-4. [IDIS 411296] [PubMed 9670876]
343. Sobel JD, Faro S, Force RW et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol. 1998; 178:203-11. [IDIS 402301] [PubMed 9500475]
344. Tobin MJ. Vulvovaginal candidiasis: topical vs. oral therapy. Am Fam Physician. 1995; 51:1715-24. [IDIS 348350] [PubMed 7754931]
345. Krieger JN. New sexually transmitted diseases treatment guidelines. J Urol. 1995; 154: 209-13.
346. Sobel JD. Controversial aspects in the management of vulvovaginal candidiasis. J Am Acad Dermatol. 1994; 31: S10-3. [IDIS 335764] [PubMed 8077494]
347. Sobel JD. Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin Infect Dis. 1992; 14(Suppl 1):S148-53.
348. Spinillo A, Capuzzo E, Gulminetti R et al. Prevalence of and risk factors for fungal vaginitis caused by non-albicans species. Am J Obstet Gynecol. 1997; 176: 138-41. [PubMed 9024104]
349. Chaim W. Fungal vaginitis caused by nonalbicans species. Am J Obstet Gynecol. 1997; 177: 485. [IDIS 393344] [PubMed 9290485]
350. Spinillo A, Capuzzo E. Fungal vaginitis caused by nonalbicans species. Am J Obstet Gynecol. 1997; 177: 485-6.
351. Redondo-Lopez V, Lynch M, Schmitt C et al. Torulopsis glabrata vaginitis: clinical aspects and susceptibility to antifungal agents. Obstet Gynecol. 1990; 76: 651-5.
352. Gupta AK, Einarson TR, Summerbell RC et al. An overview of topical antifungal therapy in dermatomycoses: a North American perspective. Drugs. 1998; 55:645-74. [PubMed 9585862]
353. Piérard GE, Arrese JE, Piérard-Franchimont C. Treatment and prophylaxis of tinea infections. Drugs. 1996; 52:209-24. [PubMed 8841739]
354. Sunenshine PJ, Schwartz RA, Janniger CK. Tinea versicolor: an update. Cutis. 1998; 61:65-72. [PubMed 9515210]
355. Assaf RR, Weil ML. The superficial mycoses. Dermatol Clin. 1996; 14:57-67. [PubMed 8821158]
356. Lesher JL. Recent developments in antifungal therapy. Dermatol Clin. 1996; 14:163-9. [PubMed 8821170]
357. Hay RJ. Dermatophytosis and other superficial mycoses. In: Mandel GL, Douglas RG Jr, Bennett JE, eds. Principles and practices of infectious disease. 4th ed. New York: Churchill Livingston; 1995: 2375-86.
358. Drake LA, Dincehart SM, Farmer ER et al. Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. J Am Acad Dermatol. 1996; 34:282-6. [IDIS 363962] [PubMed 8642094]
359. Elewski B. Tinea capitis. Dermatol Clin. 1996; 14:23-31. [PubMed 8821154]
360. Crissey JT. Common dermatophyte infections: a simple diagnostic test and current management. Postgrad Med. 1998; 103:191-205. [IDIS 401902] [PubMed 9479316]
361. Hoeschele JD, Roy AK, Pecoraro VL et al. In vitro analysis of the interaction between sucralfate and ketoconazole. Antimicrob Agents Chemother. 1994; 38:319-25. [PubMed 7910723]
362. Carver PL, Berardi RR, Knapp MJ et al. In vivo interaction of ketoconazole and sucralfate in healthy volunteers. Antimicrob Agents Chemother. 1994; 38:326-9. [IDIS 326059] [PubMed 7910724]
363. Young C, Burrows R, Katz J et al. Hypercalcaemia in sarcoidosis. Lancet. 1999; 353:374. [IDIS 419826] [PubMed 9950444]
364. Glass AR, Cerletty JM, Elliott W et al. Ketoconazole reduces elevated serum levels of 1,25-dihydroxyvitamin D in hypercalcemic sarcoidosis. J Endocrinol Invest. 1990; 13:407-13. [PubMed 2166103]
365. Bia MJ, Insogna K. Treatment of sarcoidosis-associated hypercalcemia with ketoconazole. Am J Kidney Dis. 1991; 18:702-5. [PubMed 1962657]
366. Adams JS, Sharma OP, Diz MM et al. Ketoconazole decreases the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia. J Clin Endocrinol Metab. 1990; 70:1090-5. [IDIS 285913] [PubMed 2318934]
367. Saggese G, Bertelloni S, Baroncelli GI et al. Ketoconazole decreases the serum ionized calcium and 1,25-dihydroxyvitamin D levels in tuberculosis-associated hypercalcemia. Am J Dis Child. 1993; 147:270-3. [IDIS 310648] [PubMed 8438806]
368. Sella A, Kilbourn R, Amato R et al. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol. 1994; 12:683-8. [IDIS 328740] [PubMed 7512126]
369. Ellerhorst JA, Tu SM, Amato RJ et al. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res. 1997; 3:2371-6. [IDIS 398921] [PubMed 9815636]
370. Venturoli S, Marescalchi O, Colombo FM et al. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab. 1999; 84:1304-10. [IDIS 427763] [PubMed 10199771]
371. Chapman SW, Rogers PD, Rinaldi MG et al. Susceptibilities of clinical and laboratory isolates of Blastomyces dermatitidis to ketoconazole, itraconazole, and fluconazole. Antimicrob Agents Chemother. 1998; 42:978-80. [IDIS 403759] [PubMed 9559827]
372. Paterson DL, Singh N. Interactions between tacrolimus and antimicrobial agents. Clin Infect Dis. 1997; 25:1430-40. [IDIS 398457] [PubMed 9431391]
373. Hoban DJ, Zhanel GG, Karlowsky JA. In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients. Antimicrob Agents Chemother. 1999; 43:1463-4. [PubMed 10348771]
374. Aguilar C, Pujol I, Guarro J. In vitro antifungal susceptibilities of Scopulariopsis isolates. Antimicrob Agents Chemother. 1999; 43:1520-2. [IDIS 426263] [PubMed 10348787]
375. Wheat J, Sarosi G, McKinsey D et al. Practice guidelines for the management of patients with histoplasmosis. Clin Infect Dis. 2000; 30:688-95. [IDIS 448066] [PubMed 10770731]
a. AHFS Drug Information 2004. McEvoy GK, ed. Ketoconazole. Bethesda, MD: American Society of Health-System Pharmacists; 2004:507-13.
b. Janssen Pharmaceutica. Sporanox (itraconazole) capsules prescribing information. Titusville, NJ: 2002 Feb.